LNAI: SEC Form 25 filed by Lunai Bioworks Inc.
Lunai Bioworks filed Form 25 with the SEC, voluntarily withdrawing its common stock from Nasdaq listing and registration.
What this filing says
Lunai Bioworks has filed a Form 25 notice stating it is voluntarily withdrawing its common stock from listing and registration on The Nasdaq Stock Market. The filing is made under the issuer-initiated withdrawal rule, so the company itself chose to leave the exchange. For a shareholder, this means the stock would no longer trade on Nasdaq once the removal takes effect.
Key figures
- Common stock par value
- $0.0001 per share
- Commission file number
- 001-38758
Negative for shareholders
- The common stock is set to be removed from Nasdaq listing and registration, which can reduce trading venue access and liquidity.
Written by Quantisnow AI from this filing. Not financial advice.
Key terms
- Form 25:
- A notice filed with the SEC to report that a security is being removed from an exchange listing or registration.
- Voluntary withdrawal:
- When a company chooses to remove its own stock from an exchange rather than being forced off by the exchange.
FAQ
Is Lunai Bioworks voluntarily leaving Nasdaq?
Yes, the filing checks the box for voluntary withdrawal under 17 CFR 240.12d2-2(c), stating the issuer has complied with the exchange rules for that process.
Who signed the Lunai Bioworks Form 25 filing?
The filing is signed by David Weinstein, Chief Executive Officer, and dated November 2, 2026.
Historical context for LNAI
Across the 25 sessions after earlier LNAI headlines, the stock closed higher 9 times and lower 16 times, with a median move of 4.7% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | LNAI | SPY |
|---|---|---|---|
| Oct 23, 2026 | Lunai Bioworks Announces Receipt of Nasdaq Determination and Intention to Voluntarily Delist and Deregister | -37.3% | -0.5% |
| Sep 22, 2026 | Lunai Bioworks (NASDAQ: LNAI) Expands Parkinson's Platform Through Exclusive Tanaist Agreement | -3.0% | -0.0% |
| Sep 16, 2026 | Lunai Bioworks (Nasdaq: LNAI) Demonstrates AI Chemical-Risk Screening for Generative AI | -0.9% | -0.4% |
| Sep 4, 2026 | Lunai Bioworks (NASDAQ: LNAI) Issues Correction to Press Release Regarding Second Amended Complaint | +1.7% | -0.4% |
| Aug 27, 2026 | Lunai Bioworks (Nasdaq: LNAI) Names Six Broker-Dealers in Expanded Naked Short Selling Suit | -2.1% | +0.7% |
| Aug 4, 2026 | Lunai Bioworks (Nasdaq: LNAI) Signs Definitive Collaboration Agreement with BrainStorm Therapeutics; Initial Parkinson's Disease Data Readout Targeted for First Half of 2027and 1 other headline that session | +6.7% | +1.8% |
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Follow LNAI and get a push notification the moment its next story breaks.